News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Aladote presented as a novel emerging treatment of paracetamol overdose at two scientific conferences.

February 10, 2021

Stockholm, Sweden, February 10, 2021. Egetis Therapeutics AB (publ) (ticker: EGTX) today announced that its drug candidate Aladote® will be presented at two upcoming scientific conferences in March and April.

Aladote is presented by Professor James Dear from the University of Edinburgh, UK, at the annual meeting of the Society of Toxicology (SOT) on March 16, at 11.00am ET/7.00pm CET under the heading Novel Emerging Treatments for Acetaminophen Toxicity; and at the annual scientific meeting of the American College of Medical Toxicology (ACMT) on April 14, at 5.00pm ET/11.00pm CET under the heading Antidote Updates.
Professor Dear is an internationally leading expert in the treatment of paracetamol poisoning and was the principal investigator of the Aladote phase Ib/IIa study conducted at the Royal Infirmary of Edinburgh and The Queen's Medical Research Institute, the University of Edinburgh.
Both presentations are pre-recorded talks in symposiums, followed by live Q&A sessions. No abstracts are published.



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10